enow.com Web Search

Search results

1. Results from the WOW.Com Content Network

2. Ruxolitinib - Wikipedia

   en.wikipedia.org/wiki/Ruxolitinib

   Ruxolitinib (sold under the brand names Jakafi and Jakavi among others, and as Opzelura in cream form) is a medication used for the treatment of intermediate or high-risk myelofibrosis, [6] a type of myeloproliferative neoplasm that affects the bone marrow; [11] [12] polycythemia vera, when there has been an inadequate response to or intolerance of hydroxyurea; [6] [13] and steroid-refractory ...

3. Jakafi® (ruxolitinib) Prescribing Information Updated with ...

   www.aol.com/news/2013-06-12-jakafi-ruxolitinib...

   Jakafi is a prescription medicine used to treat people with intermediate or high-risk myelofibrosis (MF), including primary MF, post-polycythemia vera MF and post-essential thrombocythemia MF.

4. New Data for Jakafi® (ruxolitinib) Presented at the 2012 ...

   www.aol.com/news/2012-12-10-new-data-for-jakafi...

   About Jakafi. Jakafi is a prescription medicine used to treat people with intermediate or high-risk myelofibrosis (MF), including primary MF, post-polycythemia vera MF and post-essential ...

5. FDA approves Incyte's treatment for chronic graft-versus-host ...

   www.aol.com/news/fda-approves-incytes-treatment...

   Jakafi is approved in the U.S. for treating acute GvHD and is considered a remedy for certain bone marrow and blood d FDA approves Incyte's treatment for chronic graft-versus-host disease Skip to ...

6. Primary myelofibrosis - Wikipedia

   en.wikipedia.org/wiki/Primary_myelofibrosis

   In November 2011, the US Food and Drug Administration (FDA) approved ruxolitinib (Jakafi) as a treatment for intermediate or high-risk myelofibrosis. [24] [25] Ruxolitinib serves as an inhibitor of JAK 1 and 2. Data from two phase III studies of ruxolitinib showed that the treatment significantly reduced spleen volume, improved symptoms of ...

7. Janus kinase inhibitor - Wikipedia

   en.wikipedia.org/wiki/Janus_kinase_inhibitor

   A Janus kinase inhibitor, also known as JAK inhibitor or jakinib, [1] is a type of immune modulating medication, which inhibits the activity of one or more of the Janus kinase family of enzymes (JAK1, JAK2, JAK3, TYK2), thereby interfering with the JAK-STAT signaling pathway in lymphocytes.

8. Medicare caps seniors drug expenses: What you need to know - AOL

   www.aol.com/news/medicare-caps-seniors-drug...

   Five cancer drugs − Revlimid, Pomalyst, Imbruvica, Jakafi, and Ibrance − cost Medicare enrollees $11,000 to nearly $15,000 per drug in 2023, according to a KFF analysis.

9. List of drugs: J - Wikipedia

   en.wikipedia.org/wiki/List_of_drugs:_J

   This multi-page article lists pharmaceutical drugs alphabetically by name. Many drugs have more than one name and, therefore, the same drug may be listed more than once. ...